• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酰核糖基羟吡嗪羧酰胺伪碱基 T-705 及其去氟类似物 T-1105 的前药作为有效的流感病毒抑制剂。

Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.

机构信息

Organic Chemistry, Department of Chemistry, Faculty of Sciences , Hamburg University , Martin-Luther-King-Platz 6 , D-20146 Hamburg , Germany.

KU Leuven, Rega Institute for Medical Research , Herestraat 49 , B-3000 Leuven , Belgium.

出版信息

J Med Chem. 2018 Jul 26;61(14):6193-6210. doi: 10.1021/acs.jmedchem.8b00617. Epub 2018 Jul 3.

DOI:10.1021/acs.jmedchem.8b00617
PMID:29906392
Abstract

We here disclose chemical synthesis of ribonucleoside 5'-monophosphate (RMP), -diphosphate (RDP), and -triphosphate (RTP) and cycloSal-, Di PPro-, and Tri PPPro nucleotide prodrugs of the antiviral pseudobase T-1105. Moreover, we include one nucleoside diphosphate prodrug of the chemically less stable T-705. We demonstrate efficient T-1105-RDP and -RTP release from the Di PPro and Tri PPPro compounds by esterase activation. Using crude enzyme extracts, we saw rapid phosphorylation of T-1105-RDP into T-1105-RTP. In sharp contrast, phosphorylation of T-1105-RMP was not seen, indicating a yet unrecognized bottleneck in T-1105's metabolic activation. Accordingly, Di PPro and Tri PPPro compounds displayed improved cell culture activity against influenza A and B virus, which they retained in a mutant cell line incapable of activating the nucleobase parent. T-1105-RTP had a strong inhibitory effect against isolated influenza polymerase, and Di PPro-T-1105-RDP showed 4-fold higher potency in suppressing one-cycle viral RNA synthesis versus T-1105. Hence, our T-1105-RDP and -RTP prodrugs improve antiviral potency and achieve efficient metabolic bypass.

摘要

我们在此披露了抗病毒假碱基 T-1105 的核糖核苷酸 5'-单磷酸(RMP)、二磷酸(RDP)和三磷酸(RTP)以及环 Sal、双 PPro 和三 PPro 核苷酸前药的化学合成。此外,我们还包括一个化学稳定性较差的 T-705 的核苷二磷酸前药。我们证明了 Di PPro 和 Tri PPPro 化合物通过酯酶激活可以有效地释放 T-1105-RDP 和 -RTP。使用粗酶提取物,我们看到 T-1105-RDP 迅速磷酸化为 T-1105-RTP。相比之下,没有观察到 T-1105-RMP 的磷酸化,这表明 T-1105 的代谢激活存在一个尚未被认识的瓶颈。因此,Di PPro 和 Tri PPPro 化合物对甲型和乙型流感病毒的细胞培养活性得到了改善,并且它们在不能激活核苷碱基母体的突变细胞系中保留了活性。T-1105-RTP 对分离的流感聚合酶具有强烈的抑制作用,而 Di PPro-T-1105-RDP 抑制一个循环病毒 RNA 合成的效力比 T-1105 高 4 倍。因此,我们的 T-1105-RDP 和 -RTP 前药提高了抗病毒效力并实现了有效的代谢旁路。

相似文献

1
Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.磷酰核糖基羟吡嗪羧酰胺伪碱基 T-705 及其去氟类似物 T-1105 的前药作为有效的流感病毒抑制剂。
J Med Chem. 2018 Jul 26;61(14):6193-6210. doi: 10.1021/acs.jmedchem.8b00617. Epub 2018 Jul 3.
2
Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir).人黄嘌呤鸟嘌呤磷酸核糖转移酶在抗病毒药物 T-705(法匹拉韦)激活中的作用。
Mol Pharmacol. 2013 Oct;84(4):615-29. doi: 10.1124/mol.113.087247. Epub 2013 Aug 1.
3
Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells.法匹拉韦(T-705)在未感染及甲型流感病毒(H5N1)感染细胞中的细胞内代谢
J Antimicrob Chemother. 2009 Oct;64(4):741-6. doi: 10.1093/jac/dkp274. Epub 2009 Jul 29.
4
Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.T-705(法匹拉韦)和利巴韦林对流感病毒复制及病毒RNA合成的不同作用
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6679-6691. doi: 10.1128/AAC.01156-16. Print 2016 Nov.
5
Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir).细胞系依赖性激活和 T-1105 的抗病毒活性,T-705(法匹拉韦)的非氟代类似物。
Antiviral Res. 2019 Jul;167:1-5. doi: 10.1016/j.antiviral.2019.04.002. Epub 2019 Apr 2.
6
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase.T-705(法匹拉韦)核糖呋喃基 5'-三磷酸对流感病毒聚合酶的碱基配对不明确和高底物效率。
PLoS One. 2013 Jul 10;8(7):e68347. doi: 10.1371/journal.pone.0068347. Print 2013.
7
Mechanism of action of T-705 against influenza virus.T-705抗流感病毒的作用机制。
Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. doi: 10.1128/AAC.49.3.981-986.2005.
8
Biochemical Evaluation of the Inhibition Properties of Favipiravir and 2'-C-Methyl-Cytidine Triphosphates against Human and Mouse Norovirus RNA Polymerases.法匹拉韦和2'-C-甲基胞苷三磷酸对人及小鼠诺如病毒RNA聚合酶抑制特性的生化评估
Antimicrob Agents Chemother. 2015 Dec;59(12):7504-16. doi: 10.1128/AAC.01391-15. Epub 2015 Sep 21.
9
Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus.针对流感病毒的嘧啶核苷单磷酸前药的合成与生物评价。
Antiviral Res. 2012 Apr;94(1):35-43. doi: 10.1016/j.antiviral.2012.01.007. Epub 2012 Jan 28.
10
Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.T-705 核糖三磷酸针对流感病毒 RNA 聚合酶的作用机制。
Antimicrob Agents Chemother. 2013 Nov;57(11):5202-8. doi: 10.1128/AAC.00649-13. Epub 2013 Aug 5.

引用本文的文献

1
MASTER-NAADP: a membrane permeable precursor of the Ca mobilizing second messenger NAADP.MASTER-NAADP:一种可通透细胞膜的钙动员第二信使 NAADP 的前体。
Nat Commun. 2024 Sep 13;15(1):8008. doi: 10.1038/s41467-024-52024-y.
2
Pharmacogenomic Studies of Antiviral Drug Favipiravir.抗病毒药物法匹拉韦的药物基因组学研究
Pharmaceutics. 2024 Apr 7;16(4):503. doi: 10.3390/pharmaceutics16040503.
3
Antiviral Activity of Lipophilic Nucleoside Tetraphosphate Compounds.疏水性核苷四磷酸化合物的抗病毒活性。
J Med Chem. 2024 Feb 22;67(4):2864-2883. doi: 10.1021/acs.jmedchem.3c02022. Epub 2024 Feb 12.
4
T-705-Derived Prodrugs Show High Antiviral Efficacies against a Broad Range of Influenza A Viruses with Synergistic Effects When Combined with Oseltamivir.T-705衍生的前药对多种甲型流感病毒显示出高抗病毒效力,与奥司他韦联合使用时有协同作用。
Pharmaceutics. 2023 Jun 14;15(6):1732. doi: 10.3390/pharmaceutics15061732.
5
Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.杀伤或灭活:核苷类似物抗 SARS-CoV-2 的作用机制和耐药性。
Antiviral Res. 2023 Feb;210:105501. doi: 10.1016/j.antiviral.2022.105501. Epub 2022 Dec 22.
6
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy.核苷类似物治疗呼吸道病毒感染:作用机制和临床疗效。
Curr Opin Virol. 2022 Dec;57:101279. doi: 10.1016/j.coviro.2022.101279. Epub 2022 Nov 17.
7
Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods.法匹拉韦及其结构类似物:抗病毒活性与合成方法。
Acta Naturae. 2022 Apr-Jun;14(2):16-38. doi: 10.32607/actanaturae.11652.
8
Prodrugs of pyrophosphates and bisphosphonates: disguising phosphorus oxyanions.焦磷酸盐和双膦酸盐的前药:磷氧阴离子的伪装
RSC Med Chem. 2022 Mar 1;13(4):375-391. doi: 10.1039/d1md00297j. eCollection 2022 Apr 20.
9
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS-CoV-2.全面更新针对由 SARS-CoV-2 引起的冠状病毒大流行的潜在药物靶点的结构和合成。
Arch Pharm (Weinheim). 2022 May;355(5):e2100382. doi: 10.1002/ardp.202100382. Epub 2022 Jan 17.
10
Improving properties of the nucleobase analogs T-705/T-1105 as potential antiviral.改善核碱基类似物T-705/T-1105作为潜在抗病毒药物的性能。
Annu Rep Med Chem. 2021;57:1-47. doi: 10.1016/bs.armc.2021.08.002. Epub 2021 Oct 28.